BeiGene announces proposed name change to ‘BeOne Medicines’
The Fly

BeiGene announces proposed name change to ‘BeOne Medicines’

BeiGene (BGNE) announced its intent to change the company’s name to “BeOne Medicines Ltd.,” confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. The new name is part of a broader strategic growth plan that has enabled the company’s global oncology leadership since its inception in 2010. The company recently reported $1B in quarterly total revenue driven by strong growth in product revenue in the U.S. and Europe. To support its expansive clinical portfolio and global growth, the company opened its $800M flagship clinical R&D and manufacturing facility at the Princeton West Innovation Campus in Hopewell, N.J. in July. Once the name is approved by shareholders, the company’s stock ticker on Nasdaq will change to “ONC”.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App